Stockreport

Theravance Biopharma: A Special Situation With A 50-100% Likely Upside [Seeking Alpha]

Viatris Inc.  (VTRS) 
PDF The company is now ~$400M in cash, $100M in 2026 milestones tied to a sales goal that was easily exceeded in 2025, and ~$60 -$70M per year in FCF. YUPELRI is the only [Read more]